SEC freezes Nasdaq’s Bitcoin options approval as CME wages jurisdictional turf war

The full SEC commission froze Nasdaq PHLX's cash-settled Bitcoin index options product on July 31, according to Crypto Briefing, after CME Group filed a jurisdictional challenge arguing Bitcoin is a commodity — not a security. That puts QBTC on ice while a public comment window runs through August 24. For traders building out multi-venue BTC options books, this is one more venue sidelined by turf wars that have nothing to do with execution quality, fill rates, or order book depth. The delay is the product. The fragmentation is the cost.

What Actually Got Killed

Nasdaq got conditional approval back in May for QBTC — options tied to the Nasdaq Bitcoin Index, which is just the CME CF Bitcoin Real Time Index sliced by 100. Yes, you read that right. The product Nasdaq wanted to launch literally runs on CME's own benchmark. CME filed its challenge around June 11, and the core argument is clean: cash-settled Bitcoin index options fall under CFTC jurisdiction, not SEC. The SEC's own conditional approval required CFTC exemptions before launch — which CME reads as the SEC trying to hand off regulatory authority it never had.

The irony is thick. Nasdaq PHLX runs one of the deepest equity options books on the planet, with established market makers, tight spreads, and serious institutional flow. A BTC-settled product there would have given derivatives traders another execution channel with proper liquidity. Instead, two federal regulators are fighting over which sandbox owns the product while the product sits dead.

The Two Ugly Outcomes

Scenario one: Nasdaq registers with the CFTC instead. New framework, new timeline, launch pushed back significantly. Scenario two: Nasdaq restructures QBTC to fit cleanly within SEC jurisdiction — a structural problem when the underlying asset is already treated as a commodity by the other federal regulator. Neither path is fast. Neither path adds order book depth anytime soon.

The CFTC has treated Bitcoin as a commodity for years. CME already runs regulated BTC futures and options under that framework, making it the incumbent in institutional Bitcoin derivatives. From CME's seat, Nasdaq is trying to onboard institutional flow through the wrong regulatory door — using CME's index as the bait. CME's argument that those CFTC exemptions can't simply shuffle regulatory authority from one agency to another is hard to dismiss.

What Serious Traders Should Do

If you were planning to route BTC options flow through Nasdaq PHLX for redundancy against Deribit and CME, scrap that plan. Capital stays concentrated on fewer venues, and concentrated liquidity means wider spreads the moment vol spikes — exactly when you need them tightest.

I'm watching three things from my seat: the August 24 comment deadline, any CFTC no-action letter filings that signal a path forward, and whether Nasdaq quietly pulls the product instead of restructuring. If the SEC doesn't rubber-stamp the original approval after August 24, expect QBTC to either morph into a CFTC product or die quietly.

The verdict: until QBTC relaunches — wherever it relaunches — your counterparty diversification on BTC options remains thinner than it should be. Don't size up on the assumption of new liquidity landing soon. Stick to venues with proven liquidation engines, real depth, and regulators who already finished their turf fight.